Bio-Gene Technology Ltd (BGT) — Capital Reinvestment Ratio

Latest as of June 2022: 0.16x

Bio-Gene Technology Ltd (BGT) has a Capital Reinvestment Ratio of 0.16x as of June 2022, meaning it reinvests 0% of its operating cash flow (AU$43.52K) in capital expenditures (AU$6.84K). Check tangible net worth ratio of Bio-Gene Technology Ltd to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.16x

Capex / Operating Cash Flow

Operating Cash Flow

AU$43.52K

AUD

Capital Expenditures

AU$6.84K

AUD

Data as of

Jun 2022

Most recent filing

Bio-Gene Technology Ltd Capital Reinvestment Ratio (2022–2022)

This chart tracks Bio-Gene Technology Ltd's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see Bio-Gene Technology Ltd (BGT) cash conversion ratio.

Annual Capital Reinvestment Ratio for Bio-Gene Technology Ltd (2022–2022)

Year-by-year Capital Reinvestment Ratio for Bio-Gene Technology Ltd from 2022 to 2022. See BGT FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Year	Reinvestment Ratio	Operating CF (AUD)	Capital Expenditures	YoY Change
2022	0.16x	AU$43.52K	AU$6.84K	—

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow